- Home
- ACLX vs IONS Comparison
ACLX vs IONS Comparison
Compare ACLX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- IONS
- Stock Information
- Founded
- ACLX 2015
- IONS 1989
- Country
- ACLX United States
- IONS United States
- Employees
- ACLX N/A
- IONS N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- IONS Health Care
- Exchange
- ACLX Nasdaq
- IONS Nasdaq
- Market Cap
- ACLX 5.3B
- IONS 6.0B
- IPO Year
- ACLX 2022
- IONS 1991
- Fundamental
- Price
- ACLX $87.83
- IONS $34.34
- Analyst Decision
- ACLX Strong Buy
- IONS Buy
- Analyst Count
- ACLX 14
- IONS 18
- Target Price
- ACLX $103.67
- IONS $62.00
- AVG Volume (30 Days)
- ACLX 667.5K
- IONS 1.1M
- Earning Date
- ACLX 11-07-2024
- IONS 11-06-2024
- Dividend Yield
- ACLX N/A
- IONS N/A
- EPS Growth
- ACLX N/A
- IONS N/A
- EPS
- ACLX N/A
- IONS N/A
- Revenue
- ACLX $155,818,000.00
- IONS $803,067,000.00
- Revenue This Year
- ACLX $20.54
- IONS N/A
- Revenue Next Year
- ACLX N/A
- IONS $16.31
- P/E Ratio
- ACLX N/A
- IONS N/A
- Revenue Growth
- ACLX 230.33
- IONS 30.57
- 52 Week Low
- ACLX $46.42
- IONS $34.24
- 52 Week High
- ACLX $107.37
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- ACLX 46.33
- IONS 26.91
- Support Level
- ACLX $99.95
- IONS $37.18
- Resistance Level
- ACLX $107.37
- IONS $40.07
- Average True Range (ATR)
- ACLX 5.90
- IONS 1.38
- MACD
- ACLX -0.23
- IONS -0.26
- Stochastic Oscillator
- ACLX 35.66
- IONS 1.58
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.